Novamind Closes Oversubscribed CAD$10 Million Private Placement
Summary
Anticipates trading on CSE under ticker symbol NM upon completion of RTO.Not for distribution to U.S. newswire services or for dissemination in the United States. The close of this $10 million round and our anticipated CSE listing are important milestones that will enable us to execute our business plan from a position of strength. Novamind is well capitalized to grow its network of outpatient mental health clinics and clinical research sites, both organically and through acquisitions, with the goal of expanding patient access to alternative mental health treatments, including psychedelic-assisted psychotherapy.Novaminds acquisition and investment strategy began in 2019 with its investment in the Synthesis Institute, a renowned legal psilocybin retreat in the Netherlands. Trading in the securities of the company should be considered highly speculative.The CSE has not in any way passed upon the merits of the Transaction and have neither approved nor disapproved the contents of this press release. There can be no assurance that the approval of the CSE regarding such listing will be obtained.All information contained in this news release with respect to Novamind and Hinterland was supplied by the parties, respectively, for inclusion herein, and each parties directors and officers have relied on each other for any information concerning such party.This news release contains forward-looking statements relating to the timing and completion of the Transaction, the Financing, the listing of the Resulting Issuer on the CSE and other statements that are not historical facts.